Author Archives: Irfan Hafiz

About Irfan Hafiz

Irfan Hafiz is a board certified physician in Infectious diseases. He has been in private practice over 10 years. He has an interest in infection control and community medicine. He does have opinions on medical issues and posts them on this blog.

Undervaccinated student at California University leads to Mumps outbreak

Just reported in MMWR is a report on a Mumps Outbreak on a University Campus — California, 2011. It just cannot be emphasized enough that vaccination is the safest, most effective way to keep these diseases of a forgotten prevaccination era out of our communities. We have become so comfortable with the notion with the safety of our world that the effect of these deadly diseases have been minimized.

Pertussis lecture 2012

Pertussis lecture

2012 update on Pertussis (Whooping cough)


This is the recording of a lecture that I gave to the hospital staff on Pertussis.

References and links

  1. CDC page on pertussis
  2. Collection of nasopharyngeal swab for pertussis
  3. Risk of seizures after whole cell pertussis or Measles, Mumps, and Rubella vaccine
  4. Ileal-lymphoid nodular hyperplasia, non-specific colitis and pervasive developmental disorder in children, Lancet 1998- the original article by AJ Wakefield that started the controversy over vaccination in the late 1990s
  5. Wikipedia article on Andrew Wakefield
  6. My comments on Wakefield findings dated January 2011
  7. Article in The Telegraph reporting on the outbreak of Measles in Liverpool

Side effects of Influenza vaccination

As we head into another influenza season we are trying to improve our hospital staff vaccination rates. The goal of vaccinating hospital staff is two fold. First to keep the staff from getting influenza themselves and second by keeping the staff from getting ill they do not become involuntary spreaders of disease to hospitalized patients. Thereby protecting the chronically ill patients at the hospital. The second reason described is often forgotten and overlooked. I cannot begin to count the number of times I have been told that they do not need a flu shot because they don’t sick from the “flu”.

Remember it is more about protecting patients, the weak and infirm who may not have the ability to tolerate a respiratory tract infection

After that discussion the next heard is concerns over vaccinating patients and how the vaccine can or will make them ill. Often cited is a concern that a post vaccination fever is not discern able from a post op fever. Archives of Internal Medicine published this study in 1996 by Nichol et al. The study, a randomized placebo controlled prospective trial looked at the number of symptoms including minor ones such as injection site pain and fever post vaccination compared to placebo. Their findings include that fever post vaccination is no more common than placebo.

Reference
JAMA Network | Archives of Internal Medicine | Side Effects Associated With Influenza Vaccination in Healthy Working AdultsA Randomized, Placebo-Controlled Trial.

Clostridium difficile- a brief review for clinicians

Clostridium difficile

Background

Clostridium difficile is a bacterium that is the most common cause of hospital acquired diarrhea.
Diarrhea due to Clostridium difficile can cause significant morbidity and sometimes mortality in the hospitalized patient. Diarrhea from this often adds to unnecessary additional hospitalization days and treatments.
The diarrhea can be refractory to treatment and can be the cause of recurrent diarrhea.
The occurrence of hospital acquired Clostridium difficile associated diarrhea (CDAD) is used as a marker of healthcare quality and factors into a hospitals overall scorecard. This will be a point in the future hospitals value based purchasing.

The following recommendations are extracts from Clinical practice guidelines for Clostridium difficle infection in Adults[1]

Organism

Clostridium difficile (CD) is an anaerobic spore forming organism that is the commonest cause of hospital acquired diarrhea.
Clostrdium difficile with spores

CD produces toxins (A & B) that can bind to colonic endothelium and result in excess secretion of fluid leading to diarrhea. Some colonic wall inflammation can be produced that in severe cases results in severe enterocolitis. This is a significant cause of nosocomial morbidity and mortality.

Definition

Clostridium difficile infection (CDI)

Presence of diarrhea with either toxin positive stool or pseudomembranes identified on endoscopy.

Diarrhea

Diarrhea is further defined as three or more unformed stools in a 24 hour period.

Transmission- current understanding

Clostridium difficile is a transmittable nosocomial pathogen[2]. Time between exposure and onset of symptoms can be as short as three days.

Most patients are CD negative on admission. Up to 30% of patients are CD positive but symptoms negative on discharge. It is believed therefore that acquisition can frequently occur in house. A subset of patients will go on the develop symptoms. [2]

It is therefore believed that transmission of spores from patient to patient occurs through asymptomatic transient healthcare provider hand contamination.[2] Attention to hand washing will break this potential transmission.

Newly colonized patients who are now subjected to alterations in the colonic bowel flora by antibiotics, proton pump inhibitors or colonic enemas will have their bowel flora changed in favor of the CD and will often go on the develop symptomatic CDAD.

Risk factors for disease

  1. Age: greater than 64 [3]
  2. Antibiotics: all antibiotics even single doses have been associated with CDI
  3. PPI: reduction in gastric acid does increase the risk of spores reaching the colon[4]
  4. Gastointestinal surgery [5]
  5. Feeding tubes [6]

Testing

  • Done only on unformed stools
  • Testing of stool from asymptomatic patients is not useful and should not be done as a test for cure
  • Repeat testing during the same episode should not be done
  • Tests
    • Toxin assay: fast turn around but not very sensitive
    • PCR assay: fast turn around and very sensitive, does not differentiate between active infectiona and colonization- more recent availability

Treatment

  1. Stop offending agents
    1. Minimizing the duration of antibiotic therapy and the spectrum of activity can reduce the duration of illness.
  2. Start empiric treatment if symptoms severe enough
    1. Metronidazole: Still first line therapy, inexpensive but can cause neuropathy with prolonged use.
    2. Oral vancomycin: If no significant improvment in 48 hours should switch to oral vancomycin 125mf four times per day. No added benefit from higher doses.
      1. Capsule: Typically dispensed by retail pharmacies if the liquid is not specifically requested and is very expensive. About $80 per day.
      2. Li quid Vancomycin: compounded by a pharmacist from a bag of IV Vancomycin is much more affordable. Aprox $30 for a month but not all pharmacies with dispense it.
    3. Fidoxamicin: Recently introduced. Currently not a first line agent. Expensive.
  3. Avoid antimotility agents like lomotil
  4. Colectomy for severe cases

Role of probiotics

  • Method of action?: Unclear how use of yeast re-establishes displaced colonic flora
  • Formulations: unstandardized
  • Data to support use?
  • Adverse effects: Risk of fungemia
  • Not recommended for primary prevention

Role of Questran

  • Mechanism of action: By binding to toxin it is believed to reduce exposure to the colonic mucosa. It can also absorb vancomycin in the bowel lumen. Not clear that it reduces duration of illness.
  • Patient tolerability

Infection control

Recomendations for active cases

  1. Gown and glove
  2. Wash hands with soap and water after caring for patients with CDAD. [7]
  3. Terminal cleaning with bleach containing cleaning agents with sufficient dwell time to disinfect surfaces.
  4. Use single use medical devices when possible.
  5. Food service handling: Do not enter room. Food try taken into room by floor staff. Used trays are moved to dirty utility room.

Prevention

  1. Handwashing between all patients [7]
  2. Judicious use of PPI [4]
  3. Antibiotic stewardship
    1. Appropriate choice of drug: restricting use of cephalosporins (except for surgical prophylaxis) and clindamycin can reduce the risk for CDI
    2. Optimal duration: minimize the duration of antibiotic therapy can reduce the risk for CDI
  4. Standardize environmental cleaning
  5. Routine environmental and personnel screening for clostridium difficile is not recommended

When to retest a patient

The short answer is probably never to retest. If the patient is clinically better then there is no indication to retest. Most patients will remain PCR or toxin positive for weeks after clinical improvement is seen.
Asymtomatic colonized patients appear to be at lower risk of development of CDI than higher. [2]

FAQ

When to discontinue contact precautions?

  • After diarrhea has resolved
  • Patient is continent of stool
  • Patient is able to take a shower

Thereby reducing the environmental contamination

What about relapsers?

  • Tapering dose of vancomycin over weeks
  • Pulse: Once week on and then a few days off. Restart when symptoms recur. The logic is that vancomycin acts on vegetative forms of CD and that giving a holiday from vancomycin will allow some spores to germinate. It is hoped that the spore reservoir is eventually exhausted.
  • Fecal transplant: Historically shown in case reports to be successful but has serious obvious limitations to widespread use due to the concern for transmission of other pathogens.

What about chronic positives without symptoms?

  • No treatment recommended
  • They do not appear to go on and have symptomatic disease

Summary of Recomendations

  • Healthcare workers and visitors must use gloves and gowns on entry to a room of a patient with CDAD
  • Physicians should be made aware of the current situation to increase their “buy-in” to the process
  • Visitors and healthcare workers must use soap and water after caring for patients with CDAD
  • Contact precautions will be maintained for the duration of diarrhea
  • Routine screening or treatment of asymptomatic patients is NOT recommended
  • Environmental testing is NOT recommended
  • Healthcare worker colonization is low, therefore screening is not recommended [8]
  • Environmental cleaning with chlorine based product is recommended. Current practices should be reviewed.
  • There is limited data to support the use of probiotics for treatment or prevention
  • Avoid anti peristaltic agents
  • Discontinuation of antimicrobial use as soon as possible is recommended
  • Efforts to identify common personnel (to find the culprit) between cases is not recommended. It is unlikely that this is a single person but rather a cultural issue. We are all to blame.
  • Continued surveillance for new cases

PPIs increase the risk for clostridium difficile says FDA

Last month the Food and Drug administration (FDA) formally put out an alert linking the risk of proton pump inhibitors (PPI) to clostridium difficile  associated diarrhea. Though this has been known for some time it was only now that the concerns have been raised to the level of a safety alert.

The PPIs are often viewed as a safe class of drug and are often started for valid reasons but not stopped even after the original indication is gone. As the incidence of recurrent and refractory clostridium difficile  becomes an every growing problem especially in the elderly who are often on PPIs it is becoming necessary to evaluate the risks and benefits of continuing PPIs long term.

 Bottom line: Stop PPIs if there is not longer a clear reason to be taking them.

Reference:

Safety Alerts for Human Medical Products > Proton Pump Inhibitors (PPIs) – Drug Safety Communication: Clostridium Difficile-Associated Diarrhea (CDAD) Can be Associated With Stomach Acid Drugs.

CDC – Seasonal Influenza Flu – Adverse Events After Receipt of TIV

Update on the 2010-11 annual influenza vaccination season related adverse effects.

Some of the notable highlights include no increase in febrile seizures in children, no increase in post vaccine fever in adults when compared to placebo (the main hesitation to give it in hospitalized patients).

Anaphylaxis or immediate hypersensitivity is estimated to be rare (1.5 case per million doses) No cases of anaphylaxis was reported in the 2010-11 season.

Botton line: adverse events related to trivalent influenza vaccine (TIV) are very rare for all age groups. It is a safe and cost effective means to reduce influenza related morbidity and mortality.

Reference:

CDC – Seasonal Influenza Flu – Adverse Events After Receipt of TIV.